Aeglea Biotherapeutics snags $44 mln Series B

Aeglea Biotherapeutics Inc, a biopharmaceutical company focused on treating tumor metabolism, has raised $44 million in Series B funding. Return backers Lilly Ventures and Novartis Venture Fund led the round with participation from other investors that included UT Horizon Fund, OrbiMed, Jennison Associates (on behalf of clients), Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group and Cowen Investments.


Dataminr scores $130 mln

Dataminr, a  real-time information discovery company, has secured $130 million in funding. Fidelity Management & Research Company led the round with participation from other investors that included Wellington Management Company LLP, Credit Suisse NEXT Investors, Venrock and Institutional Venture Partners.


On-demand parking service Luxe fetches $20 mln

San Francisco-based on-demand parking service Luxe has received $20 million in Series A funding. The investors were Venrock and Redpoint Ventures. In addition to the funding, Brian Ascher of Venrock and Ryan Sarver of Redpoint Ventures have been appointed to Luxe’s board of directors. Also, Luxe has hired Ro Choy as chief business officer.


6sense raises $20 mln, led by Bain Capital Ventures

Bain Capital Ventures has led a $20 million Series B funding round in 6sense, a SaaS-based predictive intelligence platform for marketing and sales.  Previous investors Battery Ventures and Venrock also participated in the round. The deal is the first for Indy Guha since he was promoted to partner at Bain Capital Ventures last week. As part of the funding, he will join the board of 6sense. The funding brings the total financing to $36 million for the San Francisco-based company.


VC-backed Ascendis Pharma goes public

Danish biotech firm Ascendis Pharma has raised $108 million for its IPO after pricing its 6 million shares at $18 per share. The stock begins trading Wednesday on the NASDAQ under the ticker symbol “ASND.” BofA Merrill Lynch and Leerink Partners are serving as the lead underwriters. Ascendis Pharma’s backers include Sofinnova Ventures, OrbiMed, Vivo Capital, Venrock, RA Capital Management and Janus Capital Management.


Beckon nabs $13 mln in Venrock-led round

Marketing intelligence software provider Beckon has raised $13 million in Series B funding. Venrock led the round with participation from other investors that included August Capital, Canaan Partners and El Dorado Ventures.


Regenxbio picks up $30 mln Series C

Regenxbio, a gene therapy biotech firm, has closed $30 million in Series C funding. Venrock and Brookside Capital led the round with participation from others investors that included Deerfield Management, FoxKiser and Fidelity BioSciences. Also, Camille Samuels, a partner at Venrock and Michael Gelman have been added to Regenxbio’s board of directors.


10X Genomics attracts $55.5 mln Series B

Pleasanton, California-based 10X Genomics, a genomics platform provider, has closed $55.5 million in Series B funding. Foresite Capital Management led the round with participation from other investors that included Venrock, Paladin Capital Group and Morgan Stanley Investment Management.


VC-backed Juno Therapeutics rolls out IPO

Juno Therapeutics has debuted its IPO after pricing its over 11 million shares at $24 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “JUNO.” Morgan Stanley, J.P. Morgan Securities and Goldman Sachs are the lead underwriters. Based in Seattle, Juno is a biotech company focused on developing immunotherapies for cancer. Its backers include Bezos Expeditions, Venrock, ARCH Venture Partners and the Alaska Permanent Fund.


Phononic grabs $44.5 mln Series D

Phononic has closed $44.5 million in Series D funding. Eastwood Capital Corp and the Wellcome Trust led the round with participation from WLR China Energy Infrastructure Fund, Tsing Capital, Venrock, Oak Investment Partners and Rex Health Ventures. Headquartered in Research Triangle Park, North Carolina, Phononic is a provider of solid state thermal management solutions.

VC-backed Acceleron Pharma adds to board of directors

Acceleron Pharma has appointed Dr. Francois Nader to its board of directors. Nader is president, CEO and a member of the board of directors of NPS Pharma. Acceleron Pharma’s backers include Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures and Venrock. Based in Cambridge, Mass., Acceleron is focused on developing novel protein therapeutics for cancer and rare diseases.


Deerfield leads $42.5 mln round for Audentes

San Francisco-based biotech firm Audentes Therapeutics has secured $42.5 million in Series B financing. Deerfield Management led the round with participation from Sofinnova Ventures, Venrock, OrbiMed, 5AM Ventures and Versant Ventures. As a result of the transaction, Jonathan Leff, a partner at Deerfield, will join Audentes’ board of directors.


Sofinnova Ventures, OrbiMed, Vivo Capital lead $60 mln funding in Ascendis Pharma

Sofinnova Ventures, OrbiMed and Vivo Capital have led a $60 million Series D funding in Ascendis Pharma, a biotechnology company. Other investors in the funding include Janus Capital Management, Venrock, RA Capital Management, Rock Springs Capital and Sectoral Asset Management. Ascendis Pharma’s largest shareholder, Sofinnova Partners, also participated in the funding round. James Healy of Sofinnova Ventures, Jonathan Silverstein of OrbiMed and Albert Cha of Vivo Capital have joined the company’s board of directors.


Mandalay Digital to acquire VC-backed Appia

Mandalay Digital has agreed to buy Appia, a mobile user acquisition network. According to terms of the deal, Mandalay Digital will buy Appia’s equity for $65 million based on its closing November 12 stock price of $3.40. Mandalay will also assume Appia’s approximate $10 million debt. The deal is expected to be completed in the first quarter of 2015. Appia’s backers include Venrock, Trident Capital, DCM and Eric Schmidt’s TomorrowVentures.


SheKnows acquires BlogHer to extend its reach to women online

New York-based SheKnows Media, a media company focused on women’s lifestyle, on Monday announced its acquisition of BlogHer Inc, a San Mateo, Calif.-based provider of an online network for women. SheKnows, which is a portfolio company of Great Hill Partners, said the companies will immediately combine, creating 75.3 million un-duplicated unique visitors per month. BlogHer had raised more than $15 million in funding from Venrock, Peacock Equity and NBC Universal. The acquisition price was undisclosed, although AdAge reported it to be between $30 million and $40 million.


Corsair Capital leads $50 mln Series D funding in Personal Capital

Personal Capital, a digital wealth management firm, has raised $50 million in a Series D funding round. The funding was led by Corsair Capital, as well as BBVA Ventures and USAA. Existing investors IVP, Venrock and Crosslink also participated. Jeremy Schein of Corsair will join Personal Capital’s board.


Dollar Shave Club nets $50 mln Series C

According to a company spokesperson, Venice, Calif.-based men’s lifestyle brand Dollar Shave Club has closed $50 million in Series C funding. Technology Crossover Ventures led the round with participation from Forerunner Ventures and Venrock.


Venrock leads $18 mln Series B funding in Jiff

Venrock has led an $18 million Series B funding in Jiff, a digital health technology company. Other participants in the funding included Aberdare Ventures and Aeris Capital. Jiff has raised $25.8 million since inception.

PE HUB Community

Join the 12514 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget